Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FH-006 vs investigator’s choice chemotherapy in advanced esophageal squamous cell carcinoma after PD-1/PD-L1 plus platinum failure
CTR20263313Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2026
- Countries
- 1
01
Overview
A Phase 3 trial of FH-006 in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Hengrui Therapeutics. Started Aug 2026; status: active.
02
Drugs
FH-006
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20263313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263313.